Suppr超能文献

阿托伐他汀具有剂量依赖性的肾功能和相关心血管结局的有益效应:6 项双盲随机对照试验的事后分析。

Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials.

机构信息

1 Department of Internal Medicine Amsterdam Cardiovascular Sciences Amsterdam University Medical Centre University of Amsterdam The Netherlands.

2 Division of Cardiology New York University School of Medicine New York NY.

出版信息

J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.

Abstract

Background Kidney function decreases during the lifetime, and this decline is a powerful predictor of both kidney and cardiovascular outcomes. Statins lower cardiovascular risk, which may relate to beneficial effects on kidney function. We studied whether atorvastatin influences kidney function decline and assessed the association between individual kidney function slopes and cardiovascular outcome. Methods and Results Data were collected from 6 large atorvastatin cardiovascular outcome trials conducted in patients not selected for having kidney disease. Slopes of serum creatinine reciprocals representing measures of kidney function change ([mg/dL]/y), were analyzed in 30 621 patients. Based on treatment arms, patients were categorized into 3 groups: placebo (n=10 057), atorvastatin 10 mg daily (n=12 763), and 80 mg daily (n=7801). To assess slopes, mixed-model analyses were performed for each treatment separately, including time in years and adjustment for study. These slopes displayed linear improvement over time in all 3 groups. Slope estimates for patients randomized to placebo or atorvastatin 10 mg and 80 mg were 0.009 (0.0008), 0.011 (0.0006), and 0.014 (0.0006) (mg/dL)/y, respectively. A head-to-head comparison of atorvastatin 10 and 80 mg based on data from 1 study ( TNT [Treating to New Targets]; n=10 001) showed a statistically significant difference in slope between the 2 doses ( P=0.0009). From a Cox proportional hazards model using slope as a predictor, a significant ( P<0.0001) negative association between kidney function and cardiovascular outcomes was found. Conclusions In patients at risk of or with cardiovascular disease, atorvastatin improved kidney function over time in a dose-dependent manner. In the 3 treatment groups, kidney function improvement was strongly associated with lower cardiovascular risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifiers: NCT00327418; NCT00147602; NCT00327691.

摘要

背景 肾功能会随着人的生命周期逐渐下降,其下降幅度是预测肾脏和心血管疾病的重要指标。他汀类药物可以降低心血管疾病风险,这可能与它们对肾功能的有益影响有关。我们研究了阿托伐他汀是否会影响肾功能下降,并评估了个体肾功能斜率与心血管预后之间的关系。

方法和结果 本研究数据来源于 6 项阿托伐他汀心血管结局试验,这些试验纳入的患者并非全部患有肾脏疾病。在 30621 名患者中分析了血清肌酐倒数的斜率,以代表肾功能变化的指标([mg/dL]/y)。根据治疗分组,患者被分为 3 组:安慰剂组(n=10057)、阿托伐他汀 10mg/d 组(n=12763)和 80mg/d 组(n=7801)。为了评估斜率,我们对每个治疗组分别进行了混合模型分析,包括时间(年)和研究调整。在所有 3 组中,斜率都呈线性改善。随机接受安慰剂或阿托伐他汀 10mg 和 80mg 治疗的患者斜率估计值分别为 0.009(0.0008)、0.011(0.0006)和 0.014(0.0006)(mg/dL)/y。基于 1 项研究(TNT [治疗达到新目标];n=10001)的数据进行的阿托伐他汀 10mg 和 80mg 的头对头比较显示,2 种剂量之间的斜率存在统计学差异(P=0.0009)。从斜率作为预测因子的 Cox 比例风险模型中发现,肾功能与心血管结局之间存在显著(P<0.0001)的负相关关系。

结论 在有或患有心血管疾病风险的患者中,阿托伐他汀能够使肾功能随着时间的推移呈剂量依赖性改善。在 3 个治疗组中,肾功能的改善与心血管风险的降低密切相关。

临床试验注册网址

http://www.clinicaltrials.gov。唯一标识符:NCT00327418;NCT00147602;NCT00327691。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec37/6512126/ab2faffd00eb/JAH3-8-e010827-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验